Bristol Myers to build $2.3 billion manufacturing site in Houston

Bristol Myers Squibb has announced a substantial investment of approximately $2.3 billion to build a new manufacturing facility in Houston, Texas. This new site is anticipated to create close to 500 skilled jobs within the region. The facility's primary focus will be on the production of small-molecule medicines and complex drugs, indicating an expansion of Bristol Myers Squibb's manufacturing capabilities.

In a separate development within the industrial sector, mining investor TechMet has formed a U.S. subsidiary. This strategic move is designed to attract capital specifically for critical minerals projects. TechMet, which is headquartered in Dublin, has the U.S. government listed as a major shareholder. The company's objective with this new U.S. entity is to bolster domestic production and processing of critical minerals.

These two announcements highlight significant investments in different sectors of the U.S. economy. Bristol Myers Squibb's investment points to growth in the pharmaceutical manufacturing sector, while TechMet's initiative signals efforts to strengthen the supply chain for critical minerals, a move that often aligns with national security and economic resilience goals.